I have experienced both hope and despair. In my life, they are inextricably intertwined with each other. I have come to understanding that I must celebrate both life’s low points as well as its high points. I have heard on four separate occasions, “Joel, you have cancer.” I have struggled through the impact of hearing [...]
OncoGenex Pharmaceuticals, Inc. (OGXI) announced that it's experimental product, OGX-011, also known as custirsen sodium, received fast track designation from the U.S. Food & Drug Administration (FDA) for the treatment of progressive metastatic prostate cancer in combination with first-line docetaxel treatment (chemotherapy). OGXI had previously received this same designation for second-line docetaxel treatment with OGX-011 [...]
Concerned that your diabetes could making you more vulnerable to dying from prostate cancer? Yes, diabetes sufferers should be concerned about a potential shorter life span, but not as of a result of prostate cancer (CaP). In the Journal of Clinical Oncology (September 10, 2008), Dr. Matthew Smith and his colleagues reported on the association [...]
There have been a number of articles that claim that older cancer patients report less distress than younger cancer patients report. However, this research has generally not sorted the differences among general distress, anxiety, and depression in older vs. younger survivors. Elson CJ, Weinberger MI, Balk E, Holland J, Breitbart W, Roth AJ. From the [...]
Dr. Guru Sonpavde, MD (Clinical Assistant Professor, Baylor College of Medicine) reported about an open label, phase II trial of sunitinib (Sunitinib, marketed as Sutent, and previously known as SU11248 is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and [...]